Hua Medicine's latest earnings reveal a dramatic turnaround: revenue almost doubled in 2025, hitting C¥492.9 million, while the company swung from a loss to a hefty profit. But the story doesn't end there — Hua is gearing up for expansion and patent extensions that could shape its future.
From Losses to Profits: A Sharp Reversal
Hua Medicine reported a net income of C¥1.1 billion over the trailing twelve months ending in early 2026, a massive jump from a loss of C¥250.1 million in the previous period. Basic earnings per share (EPS) rose to C¥1.12, reversing from a negative C¥0.25 the year before. Revenue climbed steadily too, moving from C¥102.7 million in the first half of 2024 to C¥217.4 million in the first half of 2025.
The surge shows Hua is doing more than just recovering; it's successfully selling its products, especially dorzagliatin, which boosted revenue. The company’s gross margin also improved, benefiting from better sales mix and operational efficiencies.
Revenue Growth vs. Earnings Forecasts: The Contradiction
But there's a puzzle: analysts expect Hua’s revenue to grow fast—about 42.6% yearly for the next three years—while earnings are predicted to fall sharply, dropping around 130.5% annually. That tension makes people wonder about the sustainability of current profits.
A key point is that Hua’s net income last year was much higher than its revenue, which is pretty unusual. It suggests that one-off gains, like a milestone payment from Bayer, helped inflate profits temporarily. The challenge now is whether Hua can maintain strong profit margins as it scales up sales and invests in international expansion.
Patent Extensions and Market Approvals Bolster Outlook
Hua Medicine recently extended patent exclusivity for dorzagliatin, its flagship diabetes drug. That extension, along with inclusion on China’s National Reimbursement Drug List (NRDL), supports the company’s long-term growth prospects. Plus, approval in Hong Kong opens doors to new markets beyond the mainland.
Management aims high with revenue goals and plans to grow sales internationally. That includes pushing dorzagliatin sales in markets where diabetes treatment demand is rising fast.
A solid cash position provides a buffer for these growth initiatives and potential R&D investments.
Valuation and Market Expectations
Even with strong recent results, Hua Medicine’s shares trade at a low multiple—about 2.7 times earnings—and are nearly 73% below what discounted cash flow models say they’re worth. Investors appear wary, likely due to the conflicting forecasts and the unusual profit-to-revenue ratio.
Still, Hua’s five-year track record shows solid earnings growth, averaging 60.2% annually before the recent dip. That history might give bulls some confidence that the current profit surge isn’t just a peak but part of a longer-term trend.
Still, skeptics want proof the company can maintain good margins while quickly growing sales and controlling costs.
Hua Medicine’s jump to profit and almost doubling revenue is a big milestone. Patent wins and expanded market approvals set the stage for growth beyond China. But with profits expected to fall even as revenue rises, investors are questioning if this success can last. Hua’s next earnings reports will be critical to watch — can it turn this profit spike into a lasting run?
